Ertumaxomab

Modify Date: 2024-04-08 17:35:11

Ertumaxomab structure	Common Name	Ertumaxomab
	CAS Number	509077-99-0	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Ertumaxomab

Ertumaxomab (Anti-Human CD22 Recombinant Antibody) is a bispecific antibody targeting HER2/neu and CD3. Ertumaxomab activates Fcγ type I/III-receptors, forming a tri-cell complex among tumour cell, T cell and accessory cell. Ertumaxomab has been used to research breast cancer[1].

Name	Ertumaxomab

Description	Ertumaxomab (Anti-Human CD22 Recombinant Antibody) is a bispecific antibody targeting HER2/neu and CD3. Ertumaxomab activates Fcγ type I/III-receptors, forming a tri-cell complex among tumour cell, T cell and accessory cell. Ertumaxomab has been used to research breast cancer[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
References	[1]. Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8.

No Any Chemical & Physical Properties

Ertumaxomab

Use of Ertumaxomab

Names

Ertumaxomab Biological Activity

Chemical & Physical Properties